-

FairJourney Biologics Expands Into New Facilities in Porto, Portugal

Newly purpose-built research center supports rapid expansion of Company

PORTO, Portugal--(BUSINESS WIRE)--FairJourney Biologics S.A. (FJB), leader in the discovery and optimization of antibodies, today announced it has relocated into a larger, newly purpose-built research center in Porto, Portugal. The new premises support the Company’s expansion and plans for further growth.

FairJourney Biologics now occupies over 200,000 square feet, with the new premises containing 140 fully equipped laboratories, meeting rooms and social areas, as well as green spaces and leisure areas to promote employee well-being. The state-of-the-art facility will house more projects and industry leading equipment, enabling the Company to support more clients and carry out world-class research into antibody-based drugs.

António Parada, CEO of FairJourney Biologics commented: “Our relocation into a new research center demonstrates our trajectory toward further growth. The move is an exciting development for the Company and gives us the flexibility to support more projects and continue to expand our market-leading antibody library.”

Contacts

Zyme Communications
Lorna Cuddon
lorna.cuddon@zymecommunications.com
Tel: +44(0)7811 996 942

FairJourney Biologics


Release Versions

Contacts

Zyme Communications
Lorna Cuddon
lorna.cuddon@zymecommunications.com
Tel: +44(0)7811 996 942

More News From FairJourney Biologics

FairJourney Biologics Appoints Dr. Werner Lanthaler as Chief Executive Officer

PORTO, Portugal--(BUSINESS WIRE)--FairJourney Biologics S.A. (FJBio), a global leader in antibody discovery and development, today announced that Dr. Werner Lanthaler has been appointed Chief Executive Officer (CEO) to further strengthen its global position as an integrated powerhouse of efficient antibody discovery and development. After nearly 14 years leading FairJourney Biologics, Founder António Parada will focus on driving FJBio’s innovation strategy on the Supervisory Board. Dr. Werner L...

FairJourney Biologics Establishes Supervisory Board

PORTO, Portugal--(BUSINESS WIRE)--FairJourney Biologics S.A., global leader in antibody discovery and development, today announced the formation of its Supervisory Board to support the Company’s ongoing strategy for growth and innovation. Comprising experienced biotech leaders with proven track records for success, the strategic initiative will focus on driving cutting-edge research, reinforcing the Company’s commitment to excellence in antibody research and to accelerate innovation in the fiel...

FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility

PORTO, Portugal & SAN FRANCISCO--(BUSINESS WIRE)--FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced that it had completed the acquisition of the South San Francisco site from Charles River Laboratories International, Inc. The acquisition aligns with FairJourney’s ongoing strategic growth plan, and will significantly bolster the Company’s antibody discovery and engineering capabilities, strengthening its technology portfolio and expanding its gl...
Back to Newsroom